Costantine Albany, MD
Medical Oncology · Lafayette, INNPI 1427381607
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $162,814 of the $211,810 with a category attached, or 76.9%. 52 manufacturers reported payments, led by Sanofi at 46.5% of the total. Reporting peaked in 2021 at $82,654 and has fallen 99.1% since, to $716 in 2025. Among medical oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $591.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$98K
- Seagen Inc.$45K
- AstraZeneca$33K
- Astellas Pharma US Inc$25K
- EMD Serono, Inc.$4K
- Beigene USA, Inc.$3K
- plus $4K from 46 others
Across 50 payments — averaging $17,542 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$539K
- Otsuka Pharmaceutical Co., Ltd.$150K
- Seagen Inc.$103K
- Bayer$44K
- Veloxis Pharmaceuticals, Inc.$41K
What the payments were for
- Consulting fees$12,7986%
- Speaking & faculty fees$162,81477%
- Travel & lodging$27,95413%
- Food & beverage$8,1464%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$211,810 in reported general payments places this provider in the 95th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 30 | $460,141 |
| JakafiRuxolitinib Phosphate | 21 | $418,486 |
| Lenalidomide | 24 | $339,286 |
| PomalystPomalidomide | 13 | $270,826 |
| TasignaNilotinib Hcl | 13 | $262,682 |
| IbrancePalbociclib | 21 | $260,534 |
| TagrissoOsimertinib Mesylate | 13 | $241,246 |
| TafinlarDabrafenib Mesylate | 12 | $173,133 |
| EliquisApixaban | 108 | $75,752 |
| XareltoRivaroxaban | 59 | $45,993 |
| Abiraterone Acetate | 25 | $26,670 |
| Enoxaparin Sodium | 15 | $8,749 |
| Exemestane | 13 | $1,999 |
| Letrozole | 44 | $1,073 |
| Potassium Chloride | 44 | $1,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $33,244 | $701,38643 claims |
| NovartisTasigna, Tafinlar | $155 | $435,81525 claims |
| Incyte CorporationJakafi | $146 | $418,48621 claims |
| PfizerIbrance, Eliquis | $159 | $336,286129 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $181 | $270,82613 claims |
| Johnson & JohnsonXarelto | $228 | $45,99359 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $50 | $26,67025 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $14 | $55440 claims |
| Lilly USA, LLCOlanzapine | $59 | $42513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Lafayette
- Vijaya KakaniLafayette$269
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
- Daniel SonnenburgIndianapolis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.